The mainstay of therapy for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) is Alexion's infusion therapy Soliris, but Novartis' iptacopan could provide an oral option after ...
NICE has recommended Alexion’s long-acting Ultomiris (ravulizumab) for the rare disease paroxysmal nocturnal haemoglobinuria (PNH) in final draft guidance. Ultomiris is Alexion’s follow-up to ...
The FDA has approved an expanded indication of Soliris, an IV-administered monoclonal antibody for patients aged 6 years and ...
The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion/AstraZeneca’s eculizumab (Soliris) for pediatric patients ...
New York, March 10, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) welcomes the U.S. Food and Drug Administration (FDA) approval of the expanded indication of Alexion ...
First approved for PNH in 2007, the monoclonal antibody is now the first and only treatment for pediatric patients living with gMG. The indicated, FDA-approved use for eculizumab (Soliris; Alexion and ...
Market Research Report for 2025 delivers a comprehensive analysis of the industry's progress, examining both historical trends and the current market landscape. It provides key insights into ...
Alexion Pharmaceuticals (NASDAQ:ALXN) is up 11% premarket on light volume in response to its announcement of successful results ...
Significant unmet need remains in PNH, a chronic, rare and potentially life-threatening blood disorder; a large proportion of patients can remain anemic and dependent on blood transfusions 3,4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback